Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yang Si

Showing results (271-280 of 284) with videos related to

Pageof 29
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLCMei-Mei Zheng, Yang-Si Li, Ben-Yuan Jiang, et al.
Science Bulletin|January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trialSi-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
Clinical Lung Cancer|October 14, 2021
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable TargetsHai-Yan Tu, Yang-Si Li, Xiao-Yan Bai, et al.
Molecular Oncology|April 20, 2023
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapyHai-Yan Tu, Kai Yin, Xiaotian Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2017
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor CellsBen-Yuan Jiang, Yang-Si Li, Wei-Bang Guo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled TrialYang-Si Li, Qitao Yu, Qing Bu, et al.
JAMA Oncology|June 13, 2024
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSong Dong, Zhen Wang, Jia-Tao Zhang, et al.
Eclinicalmedicine|October 2, 2023
Efficacy, safety and dose selection of AZD3759 in patients with untreated <i>EGFR</i>-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trialSi-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, et al.
Cell Reports. Medicine|June 19, 2024
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)Chao Zhang, Yu-Xuan Sun, Ding-Cheng Yi, et al.
Cell Reports|August 8, 2024
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLCYang-Si Li, Wen-Pu Lai, Kai Yin, et al.
Pageof 29

Showing results (271-280 of 284) with videos related to

Sort By:
Pageof 29
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLCMei-Mei Zheng, Yang-Si Li, Ben-Yuan Jiang, et al.
Science Bulletin|January 7, 2024
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trialSi-Yang Maggie Liu, Jie Huang, Jia-Yi Deng, et al.
Clinical Lung Cancer|October 14, 2021
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable TargetsHai-Yan Tu, Yang-Si Li, Xiao-Yan Bai, et al.
Molecular Oncology|April 20, 2023
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapyHai-Yan Tu, Kai Yin, Xiaotian Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2017
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor CellsBen-Yuan Jiang, Yang-Si Li, Wei-Bang Guo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled TrialYang-Si Li, Qitao Yu, Qing Bu, et al.
JAMA Oncology|June 13, 2024
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSong Dong, Zhen Wang, Jia-Tao Zhang, et al.
Eclinicalmedicine|October 2, 2023
Efficacy, safety and dose selection of AZD3759 in patients with untreated <i>EGFR</i>-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trialSi-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, et al.
Cell Reports. Medicine|June 19, 2024
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)Chao Zhang, Yu-Xuan Sun, Ding-Cheng Yi, et al.
Cell Reports|August 8, 2024
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLCYang-Si Li, Wen-Pu Lai, Kai Yin, et al.
Pageof 29